Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01139151 · ClinicalTrials.gov registry record · Phase 1
4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT01139151: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01139151 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01139151, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of 4'-thio-araC (thiarabine) that can be given to patients with advanced blood cancer. The safety of this drug will also be studied and 2 different dose schedules will be tested.
Interventions
- DRUG 3 Day Thiarabine
- DRUG 5 Day Thiarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2010-08 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01139151
The ClinicalTrials.gov registry entry for NCT01139151 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 3 Day Thiarabine is the first listed.
NCT01139151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01139151 about?
NCT01139151 is a clinical study titled "4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies". The goal of this clinical research study is to find the highest tolerable dose of 4'-thio-araC (thiarabine) that can be given to patients with advanced blood cancer. The safety of this drug will also be studied and 2 different dose schedules will be tested.
What is the current status of trial NCT01139151?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2010-08. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01139151?
The interventions under investigation include: 3 Day Thiarabine (DRUG), 5 Day Thiarabine (DRUG).
Who is sponsoring clinical trial NCT01139151?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.